WuXi PharmaTech

San Antonio’s cancer genomics partnership launches

Wednesday, November 4, 2015

The San Antonio 1000 Cancer Genomes Project (SA1kCGP), Shanghai-based WuXi NextCODE and South Texas Accelerated Research Therapeutics (START) have partnered to enable San Antonio’s pioneering citywide cancer genomics effort to contribute directly to improving the clinical treatment of cancer around the globe. The SA1kCGP brings together hundreds of doctors, oncologists and surgeons, and a thousand patients to create the basis for the resource: tumor samples from breast, lung, prostate, skin, colorectal, uterine, pancreatic, ovarian, stomach, brain cancers, collected at the time of diagnosis.

[Read More]

WuXi NextCODE partners with hospital

Friday, September 25, 2015

WuXi NextCODE, a precision medicine company using the genome to improve health worldwide, and the Children’s Hospital of Fudan University (CHFU), based in Shanghai, have partnered to advance precision medicine in China. It brings WuXi NextCODE’s genomic testing capabilities directly into clinical use for the first time in China, and builds on CHFU’s preeminence in pediatrics to immediately begin delivering benefits to thousands of rare disease patients across China.

[Read More]

Johnson & Johnson Innovation inks 17 collaborations

Friday, June 12, 2015

Johnson & Johnson Innovation has announced 17 new collaborations with research institutions and healthcare companies, bringing the total number of collaborations formed since the 2013 launch of Johnson & Johnson Innovation to more than 200. Johnson & Johnson Innovation seeks to identify and advance scientific innovation across the Johnson & Johnson segments of Pharmaceutical, Medical Devices and Consumer businesses.

[Read More]

WuXi AppTec partners with Fudan University, CICGD

Monday, June 8, 2015

Global CRO WuXi AppTec has partnered with China’s Fudan University to bring WuXi NextCODE‘s population human genomics database system and integrated research and clinical solutions to the Fudan-led Collaborative Innovation Center of Genetics and Development (CICGD) as an enterprise partner. The partnership will empower CICGD scientists to perform gene sequencing and bioinformatics analysis with unparalleled speed and precision, thereby accelerating research, clinical diagnosis and treatment of rare inherited diseases and malignant tumors.

[Read More]